Join the Zepbound group to help and get support from people like you.
Zepbound News (Page 7)
FDA Says Compounding Pharmacies Can Keep Making Weight-Loss Med Tirzepatide, for Now
TUESDAY, Oct. 15, 2024 – Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to...
GLP-1 Weight-Loss Meds, Wegovy, Zepbound, Won't Raise Teens' Suicide Risk, May Even Lower It
MONDAY, Oct. 14, 2024 – As with any new drug, parents and doctors may worry that the use of GLP-1 weight-loss meds by children and teens might raise psychiatric risks, including the risk for suicide...
Only 1 in 5 Large Companies' Health Plans Cover New Weight-Loss Meds, Wegovy, Zepbound, for Employees
WEDNESDAY, Oct. 9, 2024 – When it comes to coverage for the pricey GLP-1 weight-loss drugs Wegovy and Zepbound, only a fifth of large U.S. companies cover the medications in their health insurance...
GLP-1 Weight-Loss Meds Could Interfere With Endoscopy, Colonoscopy
TUESDAY, Oct. 1, 2024 – Food left in the stomach or stool left in the bowel can impede a doctor's ability to successfully perform an endoscopy or colonoscopy. Now, research finds this scenario is...
Cost Has Many Going Around Doctors to Get Weight-Loss Meds
WEDNESDAY, Sept. 17, 2024 – Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days. They’re in short supply, and often too expensive to afford without insurance c...
Weight-Loss Drug Zepbound May Work Better in Women Than Men
THURSDAY, Sept. 12, 2024 – The injectable weight-loss drug Zepbound appears to work better in women than in men, according to a new analysis of the clinical trials that led to its approval. All...
Taking Wegovy, Zepbound? One Expert Has Dietary Advice
TUESDAY, Sept. 3, 2024 – Folks taking weight-loss drugs like Wegovy or Zepbound might think they’ve found a shortcut to better health. But they still need to eat a high-quality diet if they want to m...
Lilly Releases Zepbound (tirzepatide) Single-Dose Vials, Expanding Supply and Access for Adults Living with Obesity
INDIANAPOLIS, Aug. 27, 2024 /PRNewswire/ – Eli Lilly and Company (NYSE: LLY) today announced Zepbound® (tirzepatide) 2.5 mg and 5 mg single-dose vials are available for self-pay for patients with an ...
Weight-Loss Drug Zepbound Now in Single-Dose Vials at Half the Price
TUESDAY, Aug. 27, 2024 – Eli Lilly, maker of one of the blockbuster GLP-1 weight-loss drug Zepbound, says it will now offer the medication in single-dose vials at half the price currently available...
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Mounjaro, Zepbound Cut Odds for Diabetes by 94% in At-Risk People, Study Finds
TUESDAY, Aug. 20, 2024 – Tirzepatide, the blockbuster GLP-1 medicine known as Mounjaro for diabetes and Zepbound for weight loss, cut the odds that an obese, prediabetic person will develop diabetes...
Risks for Mortality, Adverse Heart, Kidney Events Lower With Tirzepatide for T2DM
MONDAY, Aug. 12, 2024 – For patients with type 2 diabetes, treatment with tirzepatide (a dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist) is associated...
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
A Cardiologist Answers Your Questions on New Weight-Loss Meds, Ozempic and Zepbound
MONDAY, Feb. 12, 2024 – Weight loss drugs like Ozempic and Zepbound can lead to better heart health for people struggling with excess weight or diabetes, a University of Michigan cardiologist says....
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
Further information
Related condition support groups
Weight Loss (Obesity / Overweight), Obstructive Sleep Apnea/Hypopnea Syndrome